In other words, MultiTAA is equipped with peptides that target only 5 antigens on a tumor (cancer cells). However, MultiTAA has what is known asn an epitope spreading effect, meaning that the treatment from the company recruits other parts of the immune system to also target the tumor and to target the tumor with different antigen targets. That's important because tumors are heterogenous in nature, meaning they display multiple antigens, and not only that but they are always changing/adapting antigens. Therefore, epitope spreading takes care of eliminating cancer cells where otherwise MultiTAA wouldn't get to target.